Regeneron Pharmaceuticals (REGN) Gross Margin (2009 - 2026)

Regeneron Pharmaceuticals' Gross Margin history runs 18 years deep, the most recent figure standing at 91.79% for Q1 2026.

• On a quarterly basis, Gross Margin fell 165.0% year-over-year to 91.79% in Q1 2026; TTM through Mar 2026 was 93.36%, a 136.0% increase from a year earlier, with the FY2025 full-year figure at 93.31%, up 96.0% from the prior year.
• Gross Margin fell to 91.79% in Q1 2026 per REGN's latest filing, from 96.45% in the prior quarter.
• Across five years, Gross Margin topped out at 96.45% in Q4 2025 and bottomed at 314.6% in Q1 2022.
• The 5-year median for Gross Margin is 93.27% (2023), against an average of 53.19%.
• Across the five-year window, Gross Margin slumped 40736 bps in 2022 and jumped 40801 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 178.0% in 2022, then surged by 152 bps to 92.47% in 2023, then fell by 4 bps to 88.32% in 2024, then advanced by 9 bps to 96.45% in 2025, then slipped by 5 bps to 91.79% in 2026.
• Per Business Quant, the three latest REGN Gross Margin figures stand at 91.79% (Q1 2026), 96.45% (Q4 2025), and 92.52% (Q3 2025).